Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsBusinessCompaniesCipla gets USFDA nod for Lopinavir, Ritonavir oral pellets

    Cipla gets USFDA nod for Lopinavir, Ritonavir oral pellets

    The approval by the United States Food and Drug Administration (USFDA) is for an innovative formulation — Lopinavir/Ritonavir 40mg/ 10 mg oral pellets, Cipla said in a statement.

    June 03, 2015 / 19:58 IST
       
       
      26 Aug, 2025 12:21
      Volume
      Todays L/H
      More

      Drug major Cipla has received approval from US health regulator USFDA for Lopinavir and Ritonavir oral pellets used for treating AIDS in infants and young children.

      The approval by the United States Food and Drug Administration (USFDA) is for an innovative formulation — Lopinavir/Ritonavir 40mg/ 10 mg oral pellets, Cipla said in a statement.

       

      This novel child-friendly formulation has been approved by USFDA under the President’s Emergency Plan for AIDS Relief (PEPFAR) programme, it added.

       

      Cipla MD & Global CEO Subhanu Saxena said “This innovative way of drug delivery through oral pellets for some of society’s youngest AIDS sufferers reiterates our commitment to provide access to life saving medicines in the fight against HIV/ AIDS.”

       

      The pellets are to be sprinkled on sweetened porridge for infants and administered to them. The pellets are produced by melt-extrusion technology and are enclosed in capsules, Cipla said.

       

      “Lopinavir/Ritonavir is a preferred anti-retroviral in paediatric patents and this unique drug delivery system is a breakthrough in paediatric specific treatment for infants,” Cipla chief medical officer Jaideep Gogtay said.

       

      As per (UNAIDS — The Gap Report 2014), globally 3.2 million children were living with HIV in 2013 and 240,000 children were newly infected with HIV, Cipla said.

       
      Cipla’s current portfolio includes over 1,500 products across wide range of therapeutic categories.
      first published: Jun 3, 2015 07:01 pm

      Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

      Subscribe to Tech Newsletters

      • On Saturdays

        Find the best of Al News in one place, specially curated for you every weekend.

      • Daily-Weekdays

        Stay on top of the latest tech trends and biggest startup news.

      Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347